The continual spread of deadly pathogens coupled with the dwindling supply of antimicrobial treatments necessitates the development of effective prevention methods. However, the development of novel vaccines can be challenged by the incredible variability between microbial strains and the limitations associated with the vaccine manufacturing process.
At ATCC, we believe that it takes the combined efforts of dedicated scientists throughout the world to discover the treatments needed to keep humankind healthy and safe. That’s why we are committed to providing researchers with the virus-producing cell lines, microbial strains, and pneumococcal polysaccharides needed to support vaccine development. Together, we can work toward preventing and containing the world’s most devastating epidemics.
Browse our resources below to discover how ATCC can support your vaccine development research.
Cell Lines for Virus Production
Antiviral vaccines are essential for preventing epidemic disease; however, the production of these therapeutics is often limited by low-yielding manufacturing processes. To address this, ATCC used cutting-edge CRISPR/Cas9 gene-editing technology to develop STAT1 knockout cell lines capable of producing high-titer viral stocks.
The Vero.STAT1-KO and MDCK.STAT1-KO cell lines are not only good candidates for enhancing virus titers for vaccine development, but also useful tools to package lentiviral, adenoviral, and retroviral vectors for the delivery of DNA sequences into target cells for various applications such as gene therapy and cancer immunotherapy.
Back to top
Due to the inherent variability between microbial strains combined with their ability to rapidly evolve, new vaccines are needed ever year. Because vaccines are developed from dead or inactivated microbes or purified derivatives, it is important that scientists have access to a variety of authenticated strains known to cause infectious disease.
To support this need, ATCC provides a variety of pathogenic bacteria, viruses, and protozoa with known applications in vaccine research and development. Our growing collection of authenticated and fully characterized strains includes the causative agents of influenza, pneumonia, and whooping cough.
Back to top
Streptococcus pneumoniae is a major global health threat that is estimated to result in the death of one million children every year. While preventing the spread of this pathogenic bacterium through vaccination has been highly effective, the increasing rate of infections caused by non-vaccine serotypes presents new challenges toward containing the disease.
To aid researchers in the analysis and prevention of pneumococcal disease, ATCC offers over 30 types of pneumococcal polysaccharides from various sources. These purified polysaccharides can be used to evaluate how effectively a vaccine can induce an immune response, and they provide a unique tool for tracking the epidemiology of serotype-specific pneumococcal infections.
Back to top